ASH: Early Results Ready Lupeng’s Rocbrutinib For Potential Head-To-Head With Jaypirca

 
• By Dexter Jie Yan
  
Two assets are ready to compete
Lupeng's rocbrutinib will take on an established BTK inhibitor in a global Phase III trial. (Shutterstock)

More from ASH

More from Clinical Trials